Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion

\<Inclusion criteria\> Enrollment in the study was limited to patients who met the following inclusion criteria: 1. Subject was ≥19 years of age. 2. Subject had target limb Rutherford classification 2, 3, 4 or 5. 3. Subjects with a stenosis of 70% or greater in the femoropopliteal artery. 4. Subjects with a stenotic or occlusive lesion measuring ≥150 mm in total length. (Multiple adjacent lesions separated by less than 3 cm from angiographically healthy segments are treated as a single lesion.) 5. Subjects with a reference vessel diameter of ≥4 mm but ≤7 mm. 6. Subject provided written informed consent and was willing to comply with the study follow-up requirements. \<Exclusion criteria\> Patients were not permitted to enroll in the study if they met any of the following exclusion criteria: 1. Subjects was allergic to paclitaxel. 2. Subjects with contraindications or hypersensitivity to antiplatelet therapy. 3. Subject had life expectancy of less than 2 years. 4. Those who have undergone vascular surgery on the target lesion within the past 6 weeks. 5. Those who have in-stent restenosis (ISR) on the target lesion. 6. Those who have non-arteriosclerotic vascular disease, such as an aneurysm or vasculitis, on the target lesion. 7. Women who were pregnant, breast-feeding or intended to become pregnant. 8. Those who cannot perform pre-dilatation or who fail to apply the device, making it difficult to apply the device. 9. Those who have a Grade D or higher vascular dissection restricting blood flow after pre-dilatation or who require stent placement. 10. Those who, in the investigator's judgment, are not suitable for this study or may increase the risks associated with participation in the study.